Authors: Mihai Mareş Valentin Năstasă Florina Moraru Ramona Bogdan Doroftei Alina Ştefanache
Publish Date: 2011/07/31
Volume: 172, Issue: 6, Pages: 487-492
Abstract
The aim of the study was to evaluate the antifungal activity of a new triazole formulation against 182 clinical isolates of yeasts recovered from blood cultures in three tertiary hospitals in Romania and to compare its activity with those of fluconazole and voriconazole In vitro susceptibility was assessed by following the guidelines of AFSTEUCAST E Def 71 The distribution of minimum inhibitory concentrations MICs of MXP4509 was very similar to that of voriconazole MIC50 00312 mg/l vs 00156 mg/l MIC90 025 mg/l vs 025 mg/l but significantly different from that of fluconazole MIC50 00312 mg/l vs 05 mg/l MIC90 025 mg/l vs 32 mg/l The new triazole MXP4509 proved to have a good in vitro antifungal activity raising the interest for further pharmacological and microbiological investigations in order to assess its potential advantages for therapyThe authors are indebted to Maria Mirela Flonta Ariana Almaş Maria Cîrlan Maria Dan Doina Veronica Bilcă and Annamaria Foldes who kindly supplied some of the clinical isolates used in this study as well as Valeria Harabagiu Mariana Pinteală and Narcisa Marangoci for the synthesis of MXP4509 nanoconjugates This work was supported by the Ministry of Education and Research from Romania—CNCSISUEFISCSU project number PN IIRU 159/2010
Keywords: